Q3 FY22 Earnings Presentation

Financial summary Solid Emerging Market growth partly offset by flat U.S. results Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions ESG Appendix شا Revenue Grew 2% Y/Y; International market growth offset the impact of the COVID-19 surge in the U.S. Cardiovascular Grew 3%, driven by MSD growth in Cardiac Rhythm & Heart Failure and Structural Heart and LSD growth in Coronary & Peripheral Vascular Medical Surgical Grew 1%, or 6% ex. Ventilators, driven by strong HSD growth in Surgical Innovations, partially offset by tough comp headwinds in Respiratory, Gastrointestinal & Renal Neuroscience Grew 2%, driven by LSD growth in Cranial and Spinal Technologies and Specialty Therapies, partially offset by LSD declines in Neuromodulation Diabetes Declined 5% Y/Y and flat sequentially as we await product approvals Geographies U.S. flat; Western Europe grew MSD; Emerging Markets grew HSD led by Middle East & Africa, Latin America, and South Asia EPS & free cash flow Non-GAAP EPS $1.37, grew 6% Y/Y; YTD $4.3B free cash flow¹ All growth rates are on an organic basis unless stated otherwise. 1Operating cash flows less property, plant, and equipment additions. 6 Q3 FY22 earnings presentation | February 22, 2022 Medtronic

View entire presentation